NYSE : OGN
Organon & Co. — Key statistics
Healthcare · Drug Manufacturers - General · United States
Last price 13.81 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.63B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.63B |
| Enterprise Value | 10.73B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Aug 14, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 262.62M |
| Shares Outstanding | 262.62M |
| Shares Change (YoY) | +2.43% |
| Shares Change (QoQ) | +0.72% |
| Owned by Insiders (%) | 0.47% |
| Owned by Institutions (%) | 77.53% |
| Float | 243.06M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 17.09 |
| Forward PE | 3.83 |
| PS Ratio | 0.60 |
| Forward PS | 0.58 |
| PB Ratio | 3.05 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 5.38 |
| P/OCF Ratio | 4.31 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 50.37 |
| EV / Sales | 1.76 |
| EV / EBITDA | 6.93 |
| EV / EBIT | 8.90 |
| EV / FCF | 15.90 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.02 |
| Quick Ratio | 1.11 |
| Debt / Equity | 7.17 |
| Debt / EBITDA | 5.28 |
| Debt / FCF | 12.67 |
| Interest Coverage | 2.70 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 20.30% |
| Return on Assets (ROA) | 5.59% |
| Return on Invested Capital (ROIC) | 6.10% |
| Return on Capital Employed (ROCE) | 11.21% |
| Weighted Average Cost of Capital (WACC) | 5.34% |
| Revenue Per Employee | $609,900 |
| Profits Per Employee | $21,300 |
| Employee Count | 10,000 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 1.99 |
Taxes
| Measure | Value |
|---|
| Income Tax | 290.00M |
| Effective Tax Rate | 57.65% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.54 |
| 52-Week Price Change | +104.89% |
| 50-Day Moving Average | 13.74 |
| 200-Day Moving Average | 11.54 |
| Relative Strength Index (RSI) | 65.10 |
| Average Volume (20 Days) | 2,179,682 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 18.82M |
| Short Previous Month | 17.53M |
| Short % of Shares Out | 7.17% |
| Short % of Float | 7.74% |
| Short Ratio (days to cover) | 8.54 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 6.10B |
| Gross Profit | 3.27B |
| Operating Income | 1.21B |
| Pretax Income | 503.00M |
| Net Income | 213.00M |
| EBITDA | 1.55B |
| EBIT | 1.21B |
| Earnings Per Share (EPS) | $0.81 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.46B |
| Total Debt | 8.55B |
| Net Cash | -7.10B |
| Net Cash Per Share | -$27.03 |
| Equity (Book Value) | 1.19B |
| Book Value Per Share | 4.54 |
| Working Capital | 2.72B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 843.00M |
| Capital Expenditures | -168.00M |
| Depreciation & Amortization | 344.00M |
| Net Borrowing | -214.00M |
| Free Cash Flow | 675.00M |
| FCF Per Share | $2.57 |
Margins
| Measure | Value |
|---|
| Gross Margin | 53.65% |
| Operating Margin | 19.76% |
| Pretax Margin | 8.25% |
| Profit Margin | 3.49% |
| EBITDA Margin | 25.40% |
| EBIT Margin | 19.76% |
| FCF Margin | 11.07% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $0.08 |
| Dividend Yield | 0.58% |
| Dividend Growth (YoY) | -86.67% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 9.89% |
| FCF Payout Ratio | 3.11% |
| Buyback Yield | -2.43% |
| Shareholder Yield | -1.85% |
| Earnings Yield | 5.85% |
| FCF Yield | 18.59% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $10.33 |
| Price Target Difference | -25.28% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 1.16% |
| EPS Growth Forecast (3Y) | 1.74% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.29 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |